<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1901233119
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Valgaset
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Valganciclovir
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        450
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2499.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aurobindo Pharma Limited Unit VII" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited Unit VII
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AB14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Valgaset belongs to a group of medicines, which work directly to prevent the growth of viruses. In the<br />body the active ingredient in the tablets, valganciclovir, is changed into ganciclovir. Ganciclovir prevents<br />a virus called cytomegalovirus (CMV) from multiplying and invading healthy cells. In patients with a<br />weakened immune system, CMV can cause an infection in the body&rsquo;s organs. This can be life threatening.<br />Valgaset is used:<br />&bull; for the treatment of CMV-infections of the retina of the eye in adult patients with acquired<br />immunodeficiency syndrome (AIDS). CMV-infection of the retina of the eye can cause vision<br />problems and even blindness.<br />&bull; to pevent CMV-infections in adults and children who are not infected with CMV and who have<br />received an organ transplant from somebody who was infected by CMV.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Do not take Valgaset:<br />&bull; if you are allergic to valganciclovir, ganciclovir or any of the other ingredients of this medicine.<br />&bull; if you are breast-feeding.<br />Warnings and precautions:<br />Talk to your doctor or pharmacist before taking Valgaset:<br />&bull; if you are allergic to aciclovir, penciclovir, valaciclovir or famciclovir. These are other medicines used<br />for viral infections.<br />Take special care with Valgaset<br />&bull; if you have low numbers of white blood cells, red blood cells or platelets (small cells involved in<br />blood clotting) in your blood. Your doctor will carry out blood tests before you start taking<br />Valgasettablets and more tests will be done while you are taking the tablets.<br />&bull; if you are having radiotherapy or haemodialysis<br />&bull; if you have a problem with your kidneys. Your doctor may need to prescribe a reduced dose for you<br />and may need to check your blood frequently during treatment.<br />&bull; if you are currently taking ganciclovir capsules and your doctor wants you to switch to Valgaset<br />tablets. It is important that you do not take more than the number of tablets prescribed by your<br />doctor or you could risk an overdose.<br />Other medicines and Valgaset<br />Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other<br />medicines, including medicines obtained without a prescription.<br />If you take other medicines at the same time as taking Valgasetthe combination could affect the<br />amount of drug that gets into your blood stream or could cause harmful effects. Tell your doctor if you<br />are already taking medicines that contain any of the following:<br />&bull; imipenem-cilastatin (an antibiotic). Taking this with Valgasetcan cause convulsions (fits)<br />&bull; zidovudine, didanosine, lamivudine, stavudine, tenofovir, abacavir, emtricitabine or similar kinds of<br />drugs used to treat AIDS<br />&bull; adefovir or any other medicines used to treat Hepatitis B<br />&bull; probenecid (a medicine against gout). Taking probenecid and Valgasetat the same time could<br />increase the amount of ganciclovir in your blood<br />&bull; mycophenolate mofetil, ciclosporin or tacrolimus (used after transplantations)<br />&bull; vincristine, vinblastine, doxorubicin, hydoxyurea or similar kinds of drugs to treat cancer<br />&bull; trimethoprim, trimethoprim/sulpha combinations and dapsone (antibiotics)<br />&bull; pentamidine (drug to treat parasite or lung infections)<br />&bull; flucytosine or amphotericin B (anti-fungal agents)<br />Valgaset with food and drink<br />Valgasetshould be taken with food. If you are unable to eat for any reason, you should still take your<br />dose of Valgasetas usual.<br />Pregnancy, breast-feeding and fertility<br />You should not take Valgaset if you are pregnant unless your doctor recommends it. If you are<br />pregnant or planning to become pregnant you must tell your doctor. Taking Valgasetwhen you are<br />pregnant could harm your unborn baby.<br />You must not take Valgasetif you are breast-feeding. If your doctor wants you to begin treatment with<br />Valgasetyou must stop breast-feeding before you start to take your tablets.<br />Women of childbearing age must use effective contraception when taking Valgasetand for at least 30<br />days after treatment has finished.<br />Men whose partners could become pregnant should use condoms while taking Valgasetand should<br />continue to use condoms for 90 days after treatment has finished.<br />Driving and using machines<br />Do not drive or use any tools or machines if you feel dizzy, tired, shaky or confused while taking this<br />medicine.<br />Ask your doctor or pharmacist for advice before taking any medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or<br />pharmacist if you are not sure.<br />You have to be careful when handling your tablets. Do not break or crush them. You should swallow<br />them whole and with food whenever possible. If you accidentally touch damaged tablets, wash your<br />hands thoroughly with soap and water. If any powder from the tablets gets in your eyes, rinse your<br />eyes with sterile water or clean water if you do not have sterile water.<br />You must stick to the number of tablets as instructed by your doctor to avoid overdose.<br />Valgasettablets should, whenever possible, be taken with food.<br />Adults:<br />Prevention of CMV disease in transplant patients<br />You should start to take this medicine within 10 days of your transplant. The usual dose is two tablets<br />taken ONCE daily. You should continue with this dose for up to 100 days following your transplant. If<br />you have received a kidney transplant, your doctor may advise you to take the tablets for 200 days.<br />Treatment of active CMV retinitis in AIDS patients (called induction treatment)<br />The usual dose Valgaset is two tablets taken TWICE a day for 21 days (three weeks). Do not take this<br />dose for more than 21 days unless your doctor tells you to, as this may increase your risk of possible<br />side effects.<br />Longer term treatment to prevent recurrence of active inflammation in AIDS patients with<br />CMV retinitis (called maintenance treatment)<br />The usual dose is two tablets taken ONCE daily. You should try to take the tablets at the same time<br />each day. Your doctor will advise you how long you should continue to take Valgaset. If your retinitis<br />worsens while you are on this dose, your doctor may tell you to repeat the induction treatment (as<br />above) or may decide to give you a different medicine to treat the CMV infection.<br />Elderly patients<br />Valgaset has not been studied in elderly patients.<br />Patients with kidney problems<br />If your kidneys are not working properly, your doctor may instruct you to take fewer tablets each day or<br />only to take your tablets on certain days each week. It is very important that you only take the number<br />of tablets prescribed by your doctor.<br />Patients with liver problems<br />Valgasethas not been studied in patients with liver problems.<br />Use in children and adolescents:<br />Prevention of CMV disease in transplant patients<br />Children should start to take this medicine within 10 days of their transplant. The dose given will vary<br />depending on the size of the child and should be taken ONCE daily. Your doctor will decide the most<br />appropriate dose based on your child&rsquo;s height, weight and renal function. You should continue with this<br />dose for up to 100 days. If your child has received a kidney transplant, your doctor may advise you to<br />take the dose for 200 days.<br />For children who are unable to swallow Valgaset film-coated tables, Valgaset powder for oral solution<br />can be used.<br />If you take more Valgasetthan you should<br />Contact your doctor or hospital immediately if you have taken, or think that you have taken, more<br />tablets than you should. Taking too many tablets can cause serious side effects, particularly affecting<br />your blood or kidneys. You may need hospital treatment.<br />If you forget to take Valgaset<br />If you forget to take your tablets take the missed dose as soon as you remember and take the next<br />dose at the usual time. Do not take a double dose to make up for the forgotten tablets.<br />If you stop taking Valgaset<br />You must not stop taking your medicine unless your doctor tells you to.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Allergic reactions<br />Up to 1 in every 1,000 people may have a sudden and severe allergic reaction to valganciclovir<br />(anaphylactic shock). STOP taking Valgasetand go to the accident and emergency department at your<br />nearest hospital if you experience any of the following:<br />&bull; a raised, itchy skin rash (hives)<br />&bull; sudden swelling of the throat, face, lips and mouth which may cause difficulty swallowing or breathing<br />&bull; sudden swelling of the hands, feet or ankles.</p><p dir="ltr">Serious side effects<br />Tell your doctor straight away if you notice any of the following serious side effects &ndash; your doctor may<br />tell you to stop taking Valgaset and you may need urgent medical treatment:<br />Very common: may affect more than 1 in 10 people<br />&bull; low white blood cell counts &ndash; with signs of infection such as sore throat, mouth ulcers or a fever<br />&bull; low red blood cell counts &ndash; signs include feeling short of breath or tired, palpitations or<br />&bull; pale skin<br />Common: may affect up to 1 in 10 people<br />&bull; blood infection (sepsis) &ndash; signs include fever, chills, palpitations, confusion and slurred<br />&bull; speech<br />&bull; low level of platelets &ndash; signs include bleeding or bruising more easily than usual, blood in<br />&bull; urine or stools or bleeding from gums, the bleeding could be severe<br />&bull; severely low blood cell count<br />&bull; pancreatitis &ndash; signs are severe stomach pain which spreads into your back<br />&bull; fits<br />Uncommon: may affect up to 1 in 100 people<br />&bull; failure of the bone marrow to produce blood cells<br />&bull; hallucinations &ndash; hearing or seeing things that are not real<br />&bull; abnormal thoughts or feelings, losing contact with reality<br />&bull; failure of kidney function<br />The side effects that have occurred during treatment with valganciclovir or ganciclovir are given below.<br />Other side effects<br />Tell your doctor, pharmacist or nurse if you notice any of the following side effects:<br />Very common: may affect more than 1 in 10 people<br />&bull; thrush and oral thrush<br />&bull; upper respiratory tract infection (e.g. sinusitis, tonsillitis)<br />&bull; loss of appetite<br />&bull; headache<br />&bull; cough<br />&bull; feeling short of breath<br />&bull; diarrhoea<br />&bull; feeling or being sick<br />&bull; abdominal pain<br />&bull; eczema<br />&bull; feeling tired<br />&bull; fever.<br />Common: may affect up to 1 in 10 people<br />&bull; influenza<br />&bull; urine infection &ndash; signs include fever, passing urine more often, pain when passing urine<br />&bull; infection of the skin and the tissues under the skin<br />&bull; mild allergic reaction &ndash; the signs may include red, itchy skin<br />&bull; weight loss<br />&bull; feeling depressed, anxious or confused<br />&bull; trouble sleeping<br />&bull; hands or feet feeling weak or numb, which may affect your balance<br />&bull; changes to your sense of touch, tingling, tickling, pricking or burning feeling<br />&bull; changes to the way things taste<br />&bull; chills<br />&bull; eye inflammation (conjunctivitis), eye pain or sight problems<br />&bull; ear pain<br />&bull; low blood pressure, which may make you feel dizzy or faint<br />&bull; problems swallowing<br />&bull; constipation, wind, indigestion, stomach pain, swelling of the abdomen<br />&bull; mouth ulcers<br />&bull; abnormal results of liver and kidney laboratory tests<br />&bull; night sweats<br />&bull; itching, rash<br />&bull; hair loss<br />&bull; back pain, muscle or joint pain, muscle spasms<br />&bull; feeling dizzy, weak or generally unwell</p><p dir="ltr">Uncommon: may affect up to 1 in 100 people<br />&bull; feeling agitated<br />&bull; tremor, shaking<br />&bull; deafness<br />&bull; uneven heartbeat<br />&bull; hives, dry skin<br />&bull; blood in urine<br />&bull; infertility in men &ndash; see &lsquo;Fertility&rsquo; section<br />&bull; chest pain<br />Separation of the inner lining of the eye (detached retina) has only happened in AIDS patients treated<br />with Valgaset for CMV infection.<br />Additional side effects in children and adolescents<br />The side effects reported in children and adolescents are similar to the side effects reported for adults.<br />Reporting of side effects<br />If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side<br />effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date<br />refers to the last day of that month.<br />Store below 30&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away any medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is Valganciclovir Hydrochloride.<br />Each film coated tablet contains 496.36 mg of Valganciclovir Hydrochloride equivalent to 450 mg of<br />Valganciclovir.<br />The other ingredients are:<br />Tablet core: Cellulose Microcrystalline (PH 101), Crospovidone (Type B), Povidone (Kollidone 30),<br />Cellulose Microcrystalline (PH 102), Magnesium stearate<br />Tablet coating:<br />Opadry Pink YS-1-14519A (contains Hypromellose, Titanium Dioxide, Macrogol 400<br />Polysorbate 80 &amp; Iron Oxide Red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pink colored, oval shaped, biconvex, film-coated tablets, debossed with ‘H’ on one side and ‘96’ on
other side.
Valgaset450 mg tablets are supplied in 60’s pack (10’s Blister x 6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Manufacturer<br />Aurobindo Pharma Limited,<br />Unit VII, SEZ, TSIIC, Plot. No.S1,<br />Survey No&#39;s: 411/P, 425/P, 434/P, 435/P &amp; 458/P,<br />Green Industrial Park, Polepally Village, Jedcherla Mandal,<br />Mahaboobnagar District, Telangana State, India.<br />Marketing Authorisation Holder<br />Aurobindo Pharma Saudi Arabia Limited,<br />Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/2021, version number is 00.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي فالجاسيت لمجموعة من الأدوية تعمل مباشرة لمنع نمو الفيروسات. يتحول المكون الفعال بالأقراص -فالجانسيكلوفير- داخل الجسم إلى&nbsp;جانسيكلوفير،<br />ويمنع جانسيكلوفير فيروس يُسمى الفيروس المُضخم للخلايا (CMV) من التكاثر وغزو الخلايا السليمة.يُمكن للفيروس المُضخم للخلايا (CMV)<br />أن يتسبب في عدوى لأعضاء الجسم لدي المرضى ذوي الأجهزة المناعية الضعيفة، وقد يهدد ذلك الحياة.&nbsp;<br />يُستخدم فالجاسيت:<br />&bull; في علاج عدوات الفيروس المُضخم للخلايا بشبكية العين لدي المرضى البالغين المصابين بمتلازمة نقص المناعة المكتسبة&nbsp;(AIDS) يُمكن لعدوى .<br />الفيروس المُضخم للخلايا للعينين أن تتسبب في مشاكل بصرية قد تصل إلى العمى.<br />&bull; لمنع عدوات الفيروس المُضخم للخلايا لدي البالغين غير المصابين بالفيروس المُضخم للخلايا، والذين تلقوا أعضاء مزروعة من شخص مصاب<br />بالفيروس المُضخم للخلايا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تأخذ فالجاسيت:<br />&bull; إذا كنت مصابًا بالحساسية ضد فالجانسيكلوفير أو جانسيكلوفير أو أي مكون آخر بهذا الدواء.<br />&bull; إذا كنتِ ترضعين طبيعيًا.<br />التحذيرات والاحتياطات:<br />تحدث مع طبيبك أو الصيدلي قبل أخذ فالجاسيت:<br />&bull; إن كنت مصابًا بحساسية تجاه أسيكلوفير أو بينسيكلوفير أو فالاسيكلوفير أو فامسيكلوفير، وهي أدوية أخرى تُستخدم للعدوات الفيروسية.<br />توخى الحذر عند استخدام فالجاسيت<br />&bull; إن كانت أعداد خلايا الدم البيضاء أو خلايا الدم الحمراء أو الصفيحات ) خلايا صغيرة تساهم في تخثر الدم (منخفضة في دمك. سيُجري الطبيب<br />اختبارات للدم قبل بدء أخذ أقراص فالجاسيت، وستُجرى المزيد من الاختبارات أثناء أخذ الأقراص.<br />&bull; إن كنت خاضعًا للعلاج الإشعاعي أو غسيل الكلى.<br />&bull; إن كنت مصابًا بمشاكل في الكلى. قد يحتاج الطبيب لوصف جرعة أقل، وقد يحتاج لفحص دمك بصورة دورية أثناء العلاج.<br />&bull; إن كنت تأخذ حاليًا كبسولات جانسيكلوفير، ويرغب الطبيب في تحويلك لأقراص فالجاسيت. من المهم ألا تأخذ أكثر من عدد الأقراص التي يصفها<br />طبيبك، وإلا قد تعاني من الجرعة المفرطة.<br />الأدوية الأخرى وفالجاسيت<br />أعلم طبيبك أو الصيدلي إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أي أدوية أخرى. ويتضمن ذلك الأدوية التي تأخذها دون وصفة طبية.<br />إذا أخذت أدوية أخرى أثناء أخذ فالجاسيت، قد يؤثر هذا المزج على كمية الدواء التي تدخل لمجرى الدم، أو قد يؤدي لآثار ضارة. أعلم طبيبك إن كنت<br />تأخذ أدوية تحتوي على أي من التالي:<br />&bull; إيميبينيم-سيلاستاتين ) مضاد حيوي(. قد يؤدي أخذه مع فالجاسيت لحدوث نوبات ) تشنجات(.<br />&bull; زيدوفودين أو ديدانوسين أو لاميفودين أو ستافودين أو تينوفوفير أو أباكافير أو إيميتريسيتابين أو الأدوية المماثلة الأخرى التي تُستخدم لعلاج<br />متلازمة نقص المناعة المكتسبة&nbsp;.)AIDS(<br />&bull; أديفوفير أو أي من الأدوية الأخرى المستخدمة لعلاج الالتهاب الكبدي&nbsp;B<br />&bull; بروبينيسيد ) دواء لعلاج القلاع(. قد يؤدي أخذ بروبينيسيد وفالجاسيت في نفس الوقت إلى زيادة كمية جانسيكلوفير في الدم.<br />&bull; ميكوفينولات موفيتيل أو سيكلوسبورين أو تاكروليموس ) يُستخدموا بعد زراعة الأعضاء(.<br />&bull; فينكريستين أو فينبلاستين أو دوكسوروبيسين أو هيدروكسي يوريا أو الأدوية المماثلة الأخرى لعلاج السرطان.<br />&bull; ترايميثوبريم ومزيج ترايمويثوبريم/سالفا ودابسون ) مضادات حيوية(.<br />&bull; بينتاميدين ) دواء لعلاج الطفيليات أو عدوات الرئة(.<br />&bull; فلوسيتوسين أو أمفوتيريسين B (مضادات للفطريات).<br />فالجاسيت مع الطعام والشراب<br />يجب أخذ فالجاسيت مع الطعام. في حالة عدم قدرتك على الأكل لأي سبب من الأسباب، يجب أن تستمر في أخذ جرعتك من فالجاسيت كالمعتاد.<br />الحمل والرضاعة الطبيعية والخصوبة<br />يجب ألا تأخذي فالجاسيت أثناء الحمل إلا إن أوصى الطبيب بذلك. يجب أن تُعلمي طبيبك إن كنتِ حام ًالأو تخططين للحمل؛ لأن أخذ فالجاسيت أثناء<br />الحمل قد يضر الجنين.<br />يجب ألا تأخذين فالجاسيت إن كنتٍ تُرضعين طبيعيًا. إن رغب الطبيب في بدء العلاج بفالجاسيت، يجب أن تتوقفي عن الإرضاع قبل بدء أخذ الأقراص.<br />يجب على النساء القادرات على الإنجاب أن يستعملن وسائل منع حمل فعالة أثناء أخذ فالجاسيت وحتى 30 يومًا على الأقل بعد انتهاء العلاج.<br />يجب على الرجال استعمال الواقيات الذكرية مع قرائنهم القادرات على الإنجاب أثناء أخذ فالجاسيت، كما يجب أن يستمروا في استعمال الواقيات الذكرية<br />حتى 90 يومًا بعد انتهاء العلاج.<br />القيادة واستخدام الآلات<br />لا تقوم بالقيادة أو استعمال أي أدوات إن شعرت بالدوخة أو الإرهاق أو الارتعاش أو الارتباك أثناء أخذ هذا الدواء.<br />اطلب من طبيبك أو الصيدلي النصيحة قبل أخذ أي دواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>خذ هذا الدواء دائمًا كما أخبرك طبيبك أو الصيدلي بالضبط، وتحقق من طبيبك أو الصيدلي إن لم تكن متأكدًا.<br />يجب أن تتوخى الحذر أثناء استعمال الأقراص، ولا تكسرهم أو تطحنهم. يجب أن تبلعهم كاملين مع الطعام بقدر الإمكان. إن لمست أقراصًا تالفة عن<br />طريق الخطأ، اغسل يديك جيدًا بالماء والصابون، وإن تسرب أي مسحوق من الأقراص إلى عينيك، اغسل عينيك بماء معقم أو ماء نظيف إن كنت لا<br />تملك ماء معقم.<br />يجب أن تلتزم بعدد الأقراص كما ذكر طبيبك لتجنب الجرعة المفرطة.<br />يجب أخذ أقراص فالجاسيت مع الطعام بقدر الإمكان.<br />البالغون:<br />منع مرض الفيروس المُضخم للخلايا&nbsp;(CMV)لدي مرضى زراعة الأعضاء<br />يجب بدء أخذ هذا الدواء خلال 10 أيام من زراعة الأعضاء. الجرعة المعتادة هي قرصين يؤخذوا مرة واحدة يوميًا. يجب أن تستمر على هذه الجرعة<br />حتى 100 يوم تالية لزراعة الأعضاء. إن أجريت زراعة للكلى، قد ينصحك طبيبك بأخذ الأقراص حتى 200 يوم.<br />علاج التهاب الشبكية النشط الذي يسببه الفيروس المُضخم للخلايا&nbsp;CMV لدي مرضى متلازمة نقص المناعة المكتسبة&nbsp;AIDS<br />يُسمى علاج التحفيز<br />الجرعة المعتادة من فالجاسيت هي قرصين يؤخذوا مرتان يوميًا حتى 21 يومًا ) ثلاثة أسابيع(. لا تأخذ هذه الجرعة لأكثر من 21 يومًا مالم يطلب منك<br />الطبيب ذلك، فقد يُزيد ذلك من خطر الإصابة بآثار جانبية محتملة.<br />العلاج طويل المدى لمنع تواتر الالتهاب النشط لدي مرضى متلازمة نقص المناعة المكتسبة )AIDS( المصابين بالتهاب الشبكية الذي يُسببه<br />الفيروس المُضخم للخلايا(CMV) يُسمى علاج الحفاظ<br />الجرعة المعتادة هي قرصين يؤخذوا مرة واحدة يوميًا. يجب أن تحاول أخذ الأقراص في نفس الموعد كل يوم. سيخبرك طبيبك بمدة الاستمرار في<br />أخذ فالجاسيت. إذا تفاقم التهاب الشبكية أثناء أخذ هذه الجرعة، قد يطلب منك الطبيب تكرار علاج التحفيز ) كما هو مذكور أعلاه(، أو قد يقرر إعطاءك<br />دواء مختلف لعلاج عدوى الفيروس المُضخم للخلايا&nbsp;.)CMV(<br />المرضى كبار السن<br />لم يُدرس فالجاسيت مع المرضى كبار السن.<br />المرضى الذين يعانون من مشاكل في الكلى<br />أن كانت كليتيك لا تعملا بشكل جيد، قد يطلب منك الطبيب أخذ أقراص أقل كل يوم، أو أخذ الأقراص في أيام محددة فقط كل أسبوع. من المهم أن تأخذ<br />فقط عدد الأقراص الذي يصفه طبيبك.<br />المرضى الذين يعانون من مشاكل في الكبد<br />لم يُدرس فالجاسيت لدي المرضى المصابون بمشاكل بالكبد.<br />الاستخدام لدي الأطفال والمراهقين:<br />منع مرض الفيروس المُضخم للخلايا&nbsp;(CMV)لدي مرضى زراعة الأعضاء<br />يجب أن يبدأ الأطفال في أخذ هذا الدواء خلال 10 أيام من زراعة الأعضاء. ستتغير الجرعة المأخوذة بناءً على حجم الطفل، ويجب أن تؤخذ مرة<br />واحدة يوميًا. سيقرر الطبيب أكثر الجرعات المناسبة بناءً على طول الطفل ووزنه ووظائف كليتيه. يجب أن تستمر على هذه الجرعة حتى 100 يوم.<br />إن أجرى الطفل زراعة للكلى، قد ينصحك طبيبك بأخذ الجرعة حتى 200 يوم.<br />يمكن استعمال مسحوق فالجاسيت للمحلول الفموي مع الأطفال غير القادرين على ابتلاع أقراص فالجاسيت المغلفة.<br />إذا أخذت أكثر مما يجب من فالجاسيت<br />اتصل بالطبيب أو المستشفى على الفور إن أخذت، أو ظننت أنك أخذت، أقراصًا أكثر مما يجب.<br />قد يتسبب أخذ العديد من الأقراص في آثار جانبية خطيرة تؤثر بشكل خاص على الدم أو الكلى، وقد تحتاج لعلاج بالمستشفى.<br />إذا نسيت أخذ فالجاسيت<br />إذا نسيت أخذ أقراصك، خذ الجرعة المنسية بمجرد تذكرك، ثم خذ الجرعة التالية في الموعد المعتاد. لا تأخذ جرعة مزدوجة للتعويض عن الأقراص<br />المنسية.<br />إذا توقفت عن أخذ فالجاسيت<br />يجب ألا تتوقف عن أخذ الدواء مالم يطلب منك طبيبك فعل ذلك،<br />تحدث مع طبيبك أو الصيدلي إن كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم إصابة الجميع بها.<br />التفاعلات التحسسية<br />قد يعاني 1 من كل 1,000 شخص من تفاعل تحسسي مفاجئ وخطير تجاه فالجانسيكلوفير)صدمة تأقية(. توقف عن أخذ فالجاسيت وتوجه لقسم<br />الحوادث والطوارئ بأقرب مستشفى إن عانيت من أي من التالي:<br />&bull; طفح جلدي مرتفع تصاحبه حكة ) شرى(<br />&bull; تورم مفاجئ بالحلق والوجه والشفتين قد يتسبب في صعوبة بالبلع أو التنفس<br />&bull; تورم مفاجئ باليدين أو القدمين أو الكاحلين<br />آثار جانبية خطيرة<br />أعلم طبيبك على الفور إن لاحظت ظهور أي من الآثار الجانبية الخطيرة التالية - قد يطلب منك الطبيب التوقف عن أخذ فالجاسيت، وقد تحتاج إلى<br />علاج طبي عاجل:<br />شائعة جدًا: قد تؤثر على أكثر من 1 لكل 10 أشخاص<br />&bull; قلة أعداد خلايا الدم البيضاء - مع علامات العدوى مثل التهاب الحلق أو تقرح الفم أو الحمى<br />&bull; قلة أعداد خلايا الدم الحمراء - تتضمن العلامات الشعور بصعوبة في التنفس أو إرهاق أو خفقان أو شحوب الجلد<br />شائعة: قد تؤثر على 1 لكل 10 أشخاص<br />&bull; عدوى الدم ) إنتان (- تتضمن العلامات الحمى والارتعاش والخفقان والارتباك وصعوبة التحدث<br />&bull; انخفاض مستوى الصفيحات - تتضمن العلامات النزف أو الكدمات بصورة أكثر سهولة من المعتاد، أو دماء بالبول أو البراز أو نزف من اللثة،<br />وقد يكون النزف شديدًا.</p><p>&bull; انخفاض شديد بأعداد خلايا الدم<br />&bull; التهاب البنكرياس - وعلاماته هي ألم شديد بالمعدة ينتشر للظهر<br />&bull; نوبات<br />غير شائعة: قد تؤثر على 1 لكل 100 شخص<br />&bull; فشل نخاع العظام في إنتاج خلايا الدم<br />&bull; هلاوس - سماع أو رؤية أشياء غير حقيقية<br />&bull; أفكار أو مشاعر غير طبيعية، فقد التواصل مع الواقع<br />&bull; فشل وظائف الكلى<br />الآثار الجانبية التي حدثت أثناء العلاج فالجانسيكلوفير أو جانسيكلوفير مذكورة أدناه.<br />الآثار الجانبية الأخرى<br />أعلم طبيبك أو الصيدلي أو الممرضة إن لاحظت ظهور أي من الآثار الجانبية التالية:<br />شائعة جدًا: قد تؤثر على أكثر من 1 لكل 10 أشخاص<br />&bull; قلاع أو قلاع فموي<br />&bull; عدوى القناة التنفسية العلوية ) على سبيل المثال، التهاب الجيوب، التهاب اللهاة(<br />&bull; فقدان الشهية<br />&bull; صداع<br />&bull; سعال<br />&bull; شعور بصعوبة في التنفس<br />&bull; إسهال<br />&bull; شعور بالإعياء<br />&bull; ألم بالبطن<br />&bull; إكزيما<br />&bull; شعور بالإرهاق</p><p>&bull; حمى</p><p><br />شائعة: قد تؤثر على 1 لكل 10 أشخاص<br />&bull; إنفلونزا<br />&bull; عدوى بولية - تتضمن الأعراض الحمى وإمرار البول بصورة أكثر من المعتاد وألم أثناء التبول<br />&bull; عدوى الجلد والأنسجة تحت الجلد<br />&bull; تفاعل تحسسي ضعيف - قد تتضمن العلامات جلد أحمر تصاحبه حكة<br />&bull; فقدان الوزن<br />&bull; شعور بالاكتئاب أو القلق أو الارتباك<br />&bull; صعوبة النوم<br />&bull; شعور بالضعف أو التنميل في اليدين أو القدمين، والذي قد يؤثر على التوازن<br />&bull; تغيرات بحاسة اللمس، شعور بالتنميل أو الوخز أو النخس أو الحرق<br />&bull; تغيرات بمذاق الأشياء<br />&bull; قشعريرة<br />&bull; التهاب العينين ) التهاب الملتحمة(، ألم بالعينين أو مشاكل بالرؤية<br />&bull; ألم بالأذن<br />&bull; انخفاض ضغط الدم، والذي قد يجعلك تشعر بالدوخة أو الإغماء<br />&bull; مشاكل بالبلع<br />&bull; إمساك، ريح، عسر هضم، ألم بالمعدة، تورم بالبطن<br />&bull; قرح بالفم<br />&bull; نتائج غير طبيعية باختبارات الكبد والكلى المعملية<br />&bull; تعرق ليلي<br />&bull; حكة، طفح<br />&bull; تساقط الشعر<br />&bull; ألم بالظهر، ألم بالعضلات أو المفاصل، تشنجات عضلية<br />&bull; شعور بالدوخة أو الضعف أو الإعياء بشكل عام<br />غير شائعة: قد تؤثر على 1 لكل 100 شخص<br />&bull; شعور بالتهيج<br />&bull; هزة، رعشة<br />&bull; صمم<br />&bull; عدم انتظام نبض القلب<br />&bull; شرى، جفاف الجلد<br />&bull; دماء بالبول<br />&bull; العقم بالرجال - انظر قسم &quot;الخصوبة&quot;<br />&bull; ألم بالصدر<br />الذين عولجوا من عدوى الفيروس ) AIDS( حدث انفصال البطانة الداخلية للعين ) انفصال الشبكية (فقط لدي مرضى متلازمة نقص المناعة المكتسبة<br />باستخدام فالجاسيت. ) CMV( المُضخم للخلايا<br />آثار جانبية إضافية لدي الأطفال والمراهقين<br />الآثار الجانبية التي أُبلغ عنها لدي الأطفال والمراهقين مماثلة للآثار الجانبية المُبلغ عنها لدي البالغين.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ابق هذا الدواء بعيدا عن نظر الأطفال ومتناول أيديهم.<br />يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر. .&rdquo;EXP&ldquo; لا تستخدم هذا الدواء بعد تاريخ الانتهاء المذكور على الكرتون بعد<br />يُحفظ تحت 30 درجة مئوية.<br />لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. أسال الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه<br />التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لمادة الفعالة هي فالجانسيكلوفير هيدروكلوريد.<br />يحتوي كل قرص مُغلف على 496.36 مجم من فالجانسيكلوفير هيدروكلوريد مكافئ ل 450 مجم من فالجانسيكلوفير.<br />المكونات الأخرى هي:</p><p>جسم القرص: سيليولوز دقيق التبلور (PH 101)، كروسبوفيدون (النوعB)،&nbsp;بوفيدون ( كوليدون30) ،&nbsp;سيليولوز دقيق التبلور (PH 102)،&nbsp;ستيرات&nbsp;ماغنسيوم</p><p>غلاف القرص:</p><p>أوبادري وردي&nbsp;YS-1-14519A ، يحتوي على هييروميلوز، ثاني أكسيد التيتانيوم، ماكروجول 400 ، بولي سوربات 80 ، أكسيد حديد أحمر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يبدو فالجاسيت ومحتويات العبوة</strong><br />أقراص بيضاوية مغلفة وردية ثنائية التحدب، محفور على أحد جانبيها&nbsp;،&rdquo;H&ldquo; و&ldquo; 96 &rdquo; على الجانب الآخر.<br />تورد أقراص فالجاسيت 450 مجم في عبوة تحتوي على 60 قرص (6 أشرطة يحتوي كل منها على 10 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المُصنع<br />أوروبيندو فارما المحدودة،<br />،No.S1 ،S المنطقة الاقتصادية الخاصة، شركة البنية التحتية الصناعية بولاية تيلانجانا، قطعة رقم 1 ،VII الوحدة<br />P/425 ،P/ مسح رقم: 411<br />الحديقة الصناعية الخضراء، قرية بوليبالي، منطقة جيدشيرلا،<br />حي ماهابوباجار، ولاية تيلانجانا، الهند.<br />حامل ترخيص التسويق<br />أوروبيندو فارما السعودية المحدودة،<br />جدة، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اعتمدت هذه النشرة في 09/2021 ، رقم الإصدار هو 00  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valgaset (Valganciclovir Tablets 450 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 496.36 mg of Valganciclovir Hydrochloride equivalent to 450 mg of Valganciclovir.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pink colored, oval shaped, biconvex, film-coated tablets, debossed with ‘H’ on one side and ‘96’ on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Valganciclovir is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).</p><p dir="ltr">Valganciclovir is indicated for the prevention of CMV disease in CMV-negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMV- positive donor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">1.1&nbsp; <u>Posology</u></p><p dir="ltr"><strong>Caution &ndash; Strict adherence to dosage recommendations is essential to avoid overdose. </strong>Valganciclovir is rapidly and extensively metabolised to ganciclovir after oral dosing. Oral Valganciclovir 900 mg b.i.d. is therapeutically equivalent to intravenous ganciclovir 5 mg/kg b.i.d.</p><p dir="ltr">Treatment of cytomegalovirus (CMV) retinitis</p><p dir="ltr"><em><u>Adult patients</u></em></p><p dir="ltr"><em>Induction treatment of CMV retinitis</em></p><p dir="ltr">For patients with active CMV retinitis, the recommended dose is 900 mg Valganciclovir (two Valganciclovir 450 mg tablets) twice a day for 21 days and, whenever possible, taken with food. Prolonged induction treatment may increase the risk of bone marrow toxicity.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Maintenance treatment of CMV retinitis:</em></p><p dir="ltr">Following induction treatment, or in patients with inactive CMV retinitis, the recommended dose is 900 mg Valganciclovir (two Valganciclovir 450 mg tablets) once daily and, whenever possible, taken with food. Patients whose retinitis worsens may repeat induction treatment; however, consideration should be given to the possibility of viral drug resistance.</p><p dir="ltr">The duration of maintenance treatment should be determined on an individual basis.</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">The safety and efficacy of Valganciclovir in the treatment of CMV retinitis have not been established in adequate and well-controlled clinical studies in paediatric patients.</p><p dir="ltr">Prevention of CMV disease in solid organ transplantation</p><p dir="ltr"><em>Adult patients</em></p><p dir="ltr">For kidney transplant patients, the recommended dose is 900 mg (two Valganciclovir 450 mg tablets) once daily, starting within 10 days post-transplantation and continuing until 100 days post-transplantation. Prophylaxis may be continued until 200 days post-transplantation.</p><p dir="ltr">For patients who have received a solid organ transplant other than kidney, the recommended dose is 900 mg (two Valganciclovir 450 mg tablets) once daily, starting within 10 days post- transplantation and continuing until 100 days post-transplantation.</p><p dir="ltr">Whenever possible, the tablets should be taken with food.</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">In paediatric solid organ transplant patients, aged from birth, who are at risk of developing CMV disease, the recommended once daily dose of Valganciclovir is based on body surface area (BSA) and creatinine clearance (Clcr) derived from Schwartz formula (ClcrS), and is calculated using the equation below:</p><p dir="ltr">Paediatric Dose (mg) = 7 x BSA x ClcrS (see Mosteller BSA formula and Schwartz Creatinine Clearance formula below).</p><p dir="ltr"><!--[if gte vml 1]><o:wrapblock><v:rect
  id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
  margin-left:195.85pt;margin-top:44.1pt;width:243pt;height:31pt;z-index:251658240;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
  o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:31.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><v:shapetype
      id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
      path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
      <v:stroke joinstyle="miter"/>
      <v:formulas>
       <v:f eqn="if lineDrawn pixelLineWidth 0"/>
       <v:f eqn="sum @0 1 0"/>
       <v:f eqn="sum 0 0 @1"/>
       <v:f eqn="prod @2 1 2"/>
       <v:f eqn="prod @3 21600 pixelWidth"/>
       <v:f eqn="prod @3 21600 pixelHeight"/>
       <v:f eqn="sum @0 0 1"/>
       <v:f eqn="prod @6 1 2"/>
       <v:f eqn="prod @7 21600 pixelWidth"/>
       <v:f eqn="sum @8 21600 0"/>
       <v:f eqn="prod @7 21600 pixelHeight"/>
       <v:f eqn="sum @10 21600 0"/>
      </v:formulas>
      <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
      <o:lock v:ext="edit" aspectratio="t"/>
     </v:shapetype><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:241.8pt;
      height:30.6pt'>
      <v:imagedata src="file:///C:/Users/USER/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
       o:title=""/>
     </v:shape><span style='font-size:12.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" dir="ltr"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="327" height="45" alt="Text Box:  

" src="file:///C:/Users/USER/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></td></tr></tbody></table><p dir="ltr"><!--[if gte vml 1]></o:wrapblock><![endif]--><br />If the calculated Schwartz creatinine clearance exceeds 150 mL/min/1.73m<sup>2</sup>, then a maximum value of 150 mL/min/1.73m<sup>2</sup> should be used in the equation:</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><!--[if gte vml 1]><v:shape id="_x0000_i1025" type="#_x0000_t75"
 style='width:406.8pt;height:30.6pt'>
 <v:imagedata src="file:///C:/Users/USER/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="542" height="41" src="file:///C:/Users/USER/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p><p dir="ltr">&nbsp;</p><p dir="ltr">where k = 0.45* for patients aged &lt; 2 years, 0.55 for boys aged 2 to &lt; 13 years and girls aged 2 to 16 years, and 0.7 for boys aged 13 to 16 years. Refer to adult dosing for patients older than 16 years of age.</p><p dir="ltr">The k values provided are based on the Jaffe method of measuring serum creatinine and may require correction when enzymatic methods are used.</p><p dir="ltr">*For appropriate sub-populations a lowering of k value may also be necessary (e.g. in paediatric patients with low birth weight).</p><p dir="ltr">For paediatric kidney transplant patients, the recommended once daily mg dose (7 x BSA x ClcrS) should start within 10 days post-transplantation and continue until 200 days post- transplantation.</p><p dir="ltr">For paediatric patients who have received a solid organ transplant other than kidney, the recommended once daily mg dose (7x BSA x ClcrS) should start within 10 days post- transplantation and continue until 100 days post-transplantation.</p><p dir="ltr">All calculated doses should be rounded to the nearest 25 mg increment for the actual deliverable dose. If the calculated dose exceeds 900 mg, a maximum dose of 900 mg should be administered. The oral solution is the preferred formulation since it provides the ability to administer a dose calculated according to the formula above; however, Valganciclovir film- coated tablets may be used if the calculated doses are within 10% of available tablet doses, and the patient is able to swallow tablets. For example, if the calculated dose is between 405 mg and 495 mg, one 450 mg tablet may be taken.</p><p dir="ltr">It is recommended to monitor serum creatinine levels regularly and consider changes in height and body weight and adapt the dose as appropriate during the prophylaxis period.</p><p dir="ltr"><u>Special dosage instructions</u></p><p dir="ltr"><em>Paediatric population:</em></p><p dir="ltr">Dosing of paediatric SOT patients is individualized based on a patient&#39;s renal function, together with body surface area.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Elderly patients:</em></p><p dir="ltr">Safety and efficacy have not been established in this patient population. No studies have been conducted in adults older than 65 years of age. Since renal clearance decreases with age, Valganciclovir should be administered to elderly patients with special consideration of their renal status (see table below).</p><p dir="ltr"><em>Patients with renal impairment:</em></p><p dir="ltr">Serum creatinine levels or estimated creatinine clearance should be monitored carefully. Dosage adjustment is required according to creatinine clearance, as shown in the table below. An estimated creatinine clearance (ml/min) can be related to serum creatinine by the following formulae:</p><p dir="ltr"><!--[if gte vml 1]><o:wrapblock><v:rect
  id="_x0000_s1027" style='position:absolute;margin-left:173.5pt;margin-top:7.55pt;
  width:4in;height:31pt;z-index:251659264;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:31.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><v:shape
      id="_x0000_i1027" type="#_x0000_t75" style='width:4in;height:30.6pt'>
      <v:imagedata src="file:///C:/Users/USER/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
       o:title=""/>
     </v:shape><span style='font-size:12.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" dir="ltr"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="387" height="44" alt="Text Box:  

" src="file:///C:/Users/USER/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png" /></td></tr></tbody></table><p dir="ltr"><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">For females = 0.85 &times; male value</p><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>Clark (ml/min)</p></td><td style="vertical-align:top"><p>Induction dose of valganciclovir</p></td><td style="vertical-align:top"><p>Maintenance/Prevention dose of valganciclovir</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 60</p></td><td style="vertical-align:top"><p>900 mg (2 tablets) twice daily</p></td><td style="vertical-align:top"><p>900 mg (2 tablets) once daily</p></td></tr><tr><td style="vertical-align:top"><p>40 &ndash; 59</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) twice daily</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) once daily</p></td></tr><tr><td style="vertical-align:top"><p>25 &ndash; 39</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) once daily</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) every 2 days</p></td></tr><tr><td style="vertical-align:top"><p>10 &ndash; 24</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) every 2 days</p></td><td style="vertical-align:top"><p>450 mg (1 tablet) twice weekly</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10</p></td><td style="vertical-align:top"><p>Not recommended</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr></tbody></table><p dir="ltr"><em>Patients undergoing haemodialysis:</em></p><p dir="ltr">For patients on haemodialysis (Clcr &lt; 10 ml/min) a dose recommendation cannot be given. Thus valganciclovir film-coated tablets should not be used in these patients.</p><p dir="ltr"><em>Patients with hepatic impairment:</em></p><p dir="ltr">Safety and efficacy of valganciclovir tablets have not been established in patients with hepatic impairment.</p><p dir="ltr"><em>Patients with severe leukopenia, neutropenia, anaemia, thrombocytopenia and pancytopenia: </em>If there is a significant deterioration of blood cell counts during therapy with Valganciclovir, treatment with haematopoietic growth factors and/or dose interruption should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">Valganciclovir is administered orally, and whenever possible, should be taken with food.</p><p dir="ltr">For paediatric patients who are unable to swallow Valganciclovir film-coated tablets, valganciclovir powder for oral solution should be checked for its availability.</p><p dir="ltr"><em>Precautions to be taken before handling or administering the medicinal product</em></p><p dir="ltr">The tablets should not be broken or crushed. Since Valganciclovir is considered a potential teratogen and carcinogen in humans, caution should be observed in handling broken tablets. Avoid direct contact of broken or crushed tablets with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valganciclovir is contra-indicated in patients with hypersensitivity to valganciclovir, ganciclovir or to any of the excipients.
Valganciclovir is contra-indicated during breast-feeding.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Cross-hypersensitivity</u></p><p dir="ltr">Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible. Caution should therefore be used when prescribing valganciclovir to patients with known hypersensitivity to aciclovir or penciclovir, (or to their prodrugs, valaciclovir or famciclovir respectively).</p><p dir="ltr"><u>Mutagenicity, teratogenicity, carcinogenicity, fertility, and contraception</u></p><p dir="ltr">Prior to the initiation of valganciclovir treatment, patients should be advised of the potential risks to the foetus. In animal studies, ganciclovir was found to be mutagenic, teratogenic, carcinogenic, and a suppressor of fertility. Valganciclovir should, therefore, be considered a potential teratogen and carcinogen in humans with the potential to cause birth defects and cancers. Based on clinical and nonclinical studies it is also considered likely that valganciclovir causes temporary or permanent inhibition of spermatogenesis. Women of child bearing potential must be advised to use effective contraception during and for at least 30 days after treatment. Men must be advised to practise barrier contraception during treatment, and for at least 90 days thereafter, unless it is certain that the female partner is not at risk of pregnancy. Valganciclovir has the potential to cause carcinogenicity and reproductive toxicity in the long term.</p><p dir="ltr"><u>Myelosuppression</u></p><p dir="ltr">Severe leukopenia, neutropenia, anaemia, thrombocytopenia, pancytopenia, bone marrow failure and aplastic anaemia have been observed in patients treated with valganciclovir (and ganciclovir). Therapy should not be initiated if the absolute neutrophil count is less than 500 cells/&mu;l, or the platelet count is less than 25000/&mu;l, or the haemoglobin level is less than 8 g/dl. When extending prophylaxis beyond 100 days the possible risk of developing leukopenia and neutropenia should be taken into account.</p><p dir="ltr">Valganciclovir should be used with caution in patients with pre-existing haematological cytopenia or a history of drug-related haematological cytopenia and in patients receiving radiotherapy.</p><p dir="ltr">It is recommended that complete blood counts and platelet counts should be monitored regularly during therapy. Increased haematological monitoring may be warranted in patients with renal impairment and paediatrics, at a minimum each time the patient attends the transplant clinic. In patients developing severe leukopenia, neutropenia, anaemia and/or thrombocytopenia, it is recommended that treatment with haematopoietic growth factors and/or dose interruption be considered.</p><p dir="ltr"><u>Difference in bioavailability with oral ganciclovir</u></p><p dir="ltr">The bioavailability of ganciclovir after a single dose of 900 mg valganciclovir is approximately 60 %, compared with approximately 6 % after administration of 1000 mg oral ganciclovir (as capsules). Excessive exposure to ganciclovir may be associated with life-threatening adverse reactions. Therefore, careful adherence to the dose recommendations is advised when instituting therapy, when switching from induction to maintenance therapy and in patients who may switch from oral ganciclovir to valganciclovir as valganciclovir cannot be substituted for ganciclovir capsules on a one-to-one basis. Patients switching from ganciclovir capsules should be advised of the risk of over dosage if they take more than the prescribed number of valganciclovir tablets.</p><p dir="ltr"><u>Renal impairment</u></p><p dir="ltr">In patients with impaired renal function, dosage adjustments based on creatinine clearance are required.</p><p dir="ltr">Valganciclovir film-coated tablets should not be used in patients on haemodialysis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Use with other medicines</u></p><p dir="ltr">Seizures have been reported in patients taking imipenem-cilastatin and ganciclovir. Valganciclovir should not be used concomitantly with imipenem-cilastatin unless the potential benefits outweigh the potential risks.</p><p dir="ltr">Patients treated with valganciclovir and (a) didanosine, (b) drugs that are known to be myelosuppressive (e.g. zidovudine), or (c) substances affecting renal function, should be closely monitored for signs of added toxicity.</p><p dir="ltr">The controlled clinical study using valganciclovir for the prophylactic treatment of CMV disease in transplantation, did not include lung and intestinal transplant patients. Therefore, experience in these transplant patients is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Drug interactions with valganciclovir</u></p><p dir="ltr">In-vivo drug interaction studies with valganciclovir have not been performed. Since valganciclovir is extensively and rapidly metabolised to ganciclovir; drug interactions associated with ganciclovir will be expected for valganciclovir.</p><p dir="ltr"><u>Drug interactions with ganciclovir</u> <em><u>Pharmacokinetic interactions</u> Probenecid</em></p><p dir="ltr">Probenecid given with oral ganciclovir resulted in statistically significantly decreased renal clearance of ganciclovir (20 %) leading to statistically significantly increased exposure (40 %). These changes were consistent with a mechanism of interaction involving competition for renal tubular secretion. Therefore, patients taking probenecid and valganciclovir should be closely monitored for ganciclovir toxicity.</p><p dir="ltr"><em>Didanosine</em></p><p dir="ltr">Didanosine plasma concentrations were found to be consistently raised when given with IV ganciclovir. At intravenous doses of 5 and 10 mg/kg/day, an increase in the AUC of didanosine ranging from 38 to 67% has been observed confirming a pharmacokinetic interaction during the concomitant administration of these drugs. There was no significant effect on ganciclovir concentrations. Patients should be closely monitored for didanosine toxicity e.g pancreatitis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Other antiretrovirals</em></p><p dir="ltr">Cytochrome P450 isoenzymes play no role in ganciclovir pharmacokinetics. As a consequence, pharmacokinetic interactions with protease inhibitors and non-nucleoside reverse transcriptase inhibitors are not anticipated.</p><p dir="ltr"><em><u>Pharmacodynamic interactions</u> Imipenem-cilastatin</em></p><p dir="ltr">Seizures have been reported in patients taking ganciclovir and imipenem-cilastatin concomitantly and a pharmacodynamic interaction between these two drugs cannot be discounted. These drugs should not be used concomitantly unless the potential benefits outweigh the potential risks.</p><p dir="ltr"><em>Zidovudine</em></p><p dir="ltr">Both zidovudine and ganciclovir have the potential to cause neutropenia and anaemia. A pharmacodynamic interaction may occur during concomitant administration of these drugs. Some patients may not tolerate concomitant therapy at full dosage.</p><p dir="ltr"><em>Potential drug interactions</em></p><p dir="ltr">Toxicity may be enhanced when ganciclovir/valganciclovir is co-administered with other drugs known to be myelosuppressive or associated with renal impairment. This includes nucleoside (e.g. zidovudine, didanosine, stavudine) and nucleotide analogues (e.g. tenofovir, adefovir), immunosuppressants (e.g. ciclosporin, tacrolimus, mycophenolate mofetil), antineoplastic agents (e.g. doxorubicin, vinblastine, vincristine, hydroxyurea) and anti-infective agents (trimethoprim/sulphonamides, dapsone, amphotericin B, flucytosine, pentamidine). Therefore, these drugs should only be considered for concomitant use with valganciclovir if the potential benefits outweigh the potential risks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Contraception in males and females</u></p><p dir="ltr">As a result of the potential for reproductive toxicity and teratogenicity, women of childbearing potential must be advised to use effective contraception during and for at least 30 days after treatment. Male patients must be advised to practice barrier contraception during and for at least 90 days following treatment with valganciclovir unless it is certain that the female partner is not at risk of pregnancy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">The safety of valganciclovir for use in pregnant women has not been established. Its active metabolite, ganciclovir, readily diffuses across the human placenta. Based on its pharmacological mechanism of action and reproductive toxicity observed in animal studies with ganciclovir. There is a theoretical risk of teratogenicity in humans.</p><p dir="ltr">Valganciclovir should not be used in pregnancy unless the therapeutic benefit for the mother outweighs the potential risk of teratogenic damage to the foetus.</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">It is unknown if ganciclovir is excreted in human breast milk, but the possibility of ganciclovir being excreted in the breast milk and causing serious adverse reactions in the nursing infant cannot be discounted. Animal data indicate that ganciclovir is excreted in the milk of lactating rats. Therefore, breast-feeding must be discontinued during treatment with valganciclovir.</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">A small clinical study with renal transplant patients receiving valganciclovir for CMV prophylaxis for up to 200 days demonstrated an impact of valganciclovir on spermatogenesis, with decreased sperm density and motility measured after treatment completion. This effect appears to be reversible and approximately six months after valganciclovir discontinuation, mean sperm density and motility recovered to levels comparable to those observed in the untreated controls.</p><p dir="ltr">In animal studies, ganciclovir impaired fertility in male and female mice and has shown to inhibit spermatogenesis and induce testicular atrophy in mice, rats and dogs at doses considered clinically relevant.</p><p dir="ltr">Based on clinical and nonclinical studies, it is considered likely that ganciclovir (and valganciclovir) may cause temporary or permanent inhibition of human spermatogenesis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No studies on the effects on ability to drive and use machines have been performed.</p><p dir="ltr">Adverse reactions such as seizures, dizziness, and confusion have been reported with the use of valganciclovir and/or ganciclovir. If they occur, such effects may affect tasks requiring alertness, including the patient&#39;s ability to drive and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">a Summary of the safety profile</p><p dir="ltr">Valganciclovir is a prodrug of ganciclovir, which is rapidly and extensively metabolised to ganciclovir after oral administration. The undesirable effects known to be associated with ganciclovir use can be expected to occur with valganciclovir. All of the adverse drug reactions observed in valganciclovir clinical studies have been previously observed with ganciclovir. Therefore, adverse drug reactions reported with IV or oral ganciclovir (formulation no longer available) or with valganciclovir are included in the table of adverse drug reactions below.</p><p dir="ltr">In patients treated with valganciclovir/ganciclovir the most serious and frequent adverse drug reactions are haematological reactions and include neutropenia, anaemia and thrombocytopenia.</p><p dir="ltr">The frequencies presented in the table of adverse reactions are derived from a pooled population of patients (n=1704) receiving maintenance therapy with ganciclovir or valganciclovir. Exception is made for anaphylactic reaction, agranulocytosis and granulocytopenia, the frequencies of which are derived from post-marketing experience. Adverse reactions are listed according to MedDRA system organ class. Frequency categories are defined using the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) and very rare (&lt; 1/10,000).</p><p dir="ltr">The overall safety profile of ganciclovir/valganciclovir is consistent in HIV and transplant populations except that retinal detachment has only been reported in patients with CMV retinitis. However, there are some differences in the frequency of certain reactions. Valganciclovir is associated with a higher risk of diarrhoea compared to intravenous ganciclovir. Pyrexia, candida infections, depression, severe neutropenia (ANC &lt;500/&mu;L) and skin reactions are reported more frequently in patients with HIV. Renal and hepatic dysfunction are reported more frequently in organ transplant recipients.</p><p dir="ltr">&nbsp;</p><p dir="ltr">b Tabulated list of adverse drug reactions</p><p dir="ltr"><strong><em>&nbsp;</em></strong></p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p style="margin-left:160px"><strong>ADR (MedDRA)</strong></p><p style="margin-left:160px"><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p style="margin-left:160px"><strong>Frequency Category</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:160px"><strong><em>Infections and infestations:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Candida infections including oral candidiasis.</p></td><td rowspan="2" style="vertical-align:top"><p style="margin-left:160px">Very common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Upper respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Sepsis</p></td><td rowspan="4" style="vertical-align:top"><p style="margin-left:160px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:160px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:160px">Common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Influenza</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Urinary tract infection</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Cellulitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:160px"><strong><em>Blood and lymphatic disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Neutropenia</p></td><td rowspan="2" style="vertical-align:top"><p style="margin-left:160px">Very common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Anaemia</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Thrombocytopenia</p></td><td rowspan="3" style="vertical-align:top"><p style="margin-left:160px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:160px">Common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Leukopenia</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Bone marrow failure</p></td><td style="vertical-align:top"><p style="margin-left:160px">Uncommon</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Aplastic anaemia</p></td><td rowspan="3" style="vertical-align:top"><p style="margin-left:160px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:160px">Rare</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Agranulocytosis*</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Granulocytopenia*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:160px"><strong><em>Immune system disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Hypersensitivity</p></td><td style="vertical-align:top"><p style="margin-left:160px">Common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Anaphylactic reaction*</p></td><td style="vertical-align:top"><p style="margin-left:160px">Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:160px"><strong><em>Metabolic and nutrition disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Decreased appetite</p></td><td style="vertical-align:top"><p style="margin-left:160px">Very common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Weight decreased</p></td><td style="vertical-align:top"><p style="margin-left:160px">Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:160px"><strong><em>Psychiatric disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Depression</p></td><td rowspan="3" style="vertical-align:top"><p style="margin-left:160px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:160px">Common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Confusional state</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Anxiety</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Agitation</p></td><td rowspan="4" style="vertical-align:top"><p style="margin-left:160px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:160px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:160px">Uncommon</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Psychotic disorder</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Thinking abnormal</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Hallucinations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:160px"><strong><em>Nervous system disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:160px">Headache</p></td><td style="vertical-align:top"><p style="margin-left:160px">Very common</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p style="margin-left:120px">Insomnia</p></td><td rowspan="7" style="vertical-align:top"><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px">Common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Neuropathy peripheral</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Dizziness</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Hypoaesthesia</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Seizure</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Dysgeusia (taste disturbance)</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Tremor</p></td><td style="vertical-align:top"><p style="margin-left:120px">Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:120px"><strong><em>Eye disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Visual impairment</p></td><td rowspan="6" style="vertical-align:top"><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px">Common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Retinal detachment**</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Vitreous floaters</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Eye pain</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Conjunctivitis</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Macular oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:120px"><strong><em>Ear and labyrinth disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Ear pain</p></td><td style="vertical-align:top"><p style="margin-left:120px">Common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Deafness</p></td><td style="vertical-align:top"><p style="margin-left:120px">Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:120px"><strong><em>Cardiac disorders </em></strong><em>:</em></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Arrhythmias</p></td><td style="vertical-align:top"><p style="margin-left:120px">Uncommon</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px"><strong><em>Vascular disorders </em></strong><em>:</em></p></td><td style="vertical-align:top"><p style="margin-left:120px">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Hypotension</p></td><td style="vertical-align:top"><p style="margin-left:120px">Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:120px"><strong><em>Respiratory, thoracic and mediastinal disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Cough</p></td><td rowspan="2" style="vertical-align:top"><p style="margin-left:120px">Very common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Dyspnoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="margin-left:120px"><strong><em>Gastrointestinal disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Diarrhoea</p></td><td rowspan="4" style="vertical-align:top"><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px">Very common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Nausea</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Vomiting</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Dyspepsia</p></td><td rowspan="5" style="vertical-align:top"><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px"><strong><em>&nbsp;</em></strong></p><p style="margin-left:120px">Common</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Flatulence</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Abdominal pain upper</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Constipation</p></td></tr><tr><td style="vertical-align:top"><p style="margin-left:120px">Mouth ulceration</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>Dysphagia</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal distention</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Hepato-biliary disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td><td rowspan="4" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissues disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Night sweats</p></td><td rowspan="4" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td rowspan="2" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Musculo-skeletal and connective tissue disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td rowspan="4" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Renal and urinary disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Renal impairment</p></td><td rowspan="3" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance renal decreased</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Renal failure</p></td><td rowspan="2" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Reproductive system and breast disorders:</em></strong></p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>Infertility male</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>General disorders and administration site conditions:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td rowspan="2" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td rowspan="4" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p dir="ltr"><em>*The frequencies of these adverse reactions are derived from post-marketing experience</em></p><p dir="ltr"><em>**Retinal detachment has only been reported in HIV patients treated for CMV retinitis</em></p><p dir="ltr">Description of selected adverse reactions</p><p dir="ltr"><em>Neutropenia</em></p><p dir="ltr">The risk of neutropenia is not predictable on the basis of the number of neutrophils before treatment. Neutropenia usually occurs during the first or second week of induction therapy. The cell count usually normalises within 2 to 5 days after discontinuation of the drug or dose reduction.</p><p dir="ltr"><em>Thrombocytopenia</em></p><p dir="ltr">Patients with low baseline platelet counts (&lt; 100,000 /&mu;L) have an increased risk of developing thrombocytopenia. Patients with iatrogenic immunosuppression due to treatment with immunosuppressive drugs are at greater risk of thrombocytopenia than patients with AIDS. Severe thrombocytopenia may be associated with potentially life-threatening bleeding.</p><p dir="ltr"><em>Influence of treatment duration or indication on adverse reactions</em></p><p dir="ltr">Severe neutropenia (ANC &lt;500/&mu;L) is seen more frequently in CMV retinitis patients (14%) undergoing treatment with valganciclovir, intravenous or oral ganciclovir than in solid organ transplant patients receiving valganciclovir or oral ganciclovir. In patients receiving valganciclovir or oral ganciclovir until Day 100 post-transplant, the incidence of severe neutropenia was 5% and 3% respectively, whilst in patients receiving valganciclovir until Day 200 post-transplant the incidence of severe neutropenia was 10%.</p><p dir="ltr">There was a greater increase in serum creatinine seen in solid organ transplant patients treated until Day 100 or Day 200 post-transplant with both valganciclovir and oral ganciclovir when</p><p dir="ltr">&nbsp;</p><p dir="ltr">compared to CMV retinitis patients. However, impaired renal function is a feature common in solid organ transplantation patients.</p><p dir="ltr">The overall safety profile of valganciclovir did not change with the extension of prophylaxis up to 200 days in high risk kidney transplant patients. Leukopenia was reported with a slightly higher incidence in the 200 days arm while the incidence of neutropenia, anaemia and thrombocytopenia were similar in both arms.</p><p dir="ltr">c Paediatric population</p><p dir="ltr">Valganciclovir has been studied in 179 paediatric solid organ transplant patients who were at risk of developing CMV disease (aged 3 weeks to 16 years) and in 133 neonates with symptomatic congenital CMV disease (aged 2 to 31 days), with duration of ganciclovir exposure ranging from 2 to 200 days.</p><p dir="ltr">The most frequently reported adverse reactions on treatment in paediatric clinical trials were diarrhoea, nausea, neutropenia, leukopenia and anaemia.</p><p dir="ltr">In solid organ transplant patients, the overall safety profile was similar in paediatric patients as compared to adults. Neutropenia was reported with slightly higher incidence in the two studies conducted in paediatric solid organ transplant patients as compared to adults, but there was no correlation between neutropenia and infectious adverse events in the paediatric population. A higher risk of cytopenias in neonates and infants warrants careful monitoring of blood counts in these age groups.</p><p dir="ltr">In kidney transplant paediatric patients, prolongation of valganciclovir exposure up to 200 days was not associated with an overall increase in the incidence of adverse events. The incidence of severe neutropenia (ANC &lt; 500/&micro;L) was higher in paediatric kidney patients treated until Day 200 as compared to paediatric patients treated until Day 100 and as compared to adult kidney transplant patients treated until Day 100 or Day 200.</p><p dir="ltr">Only limited data are available in neonates or infants with symptomatic congenital CMV infection treated with valganciclovir, however the safety appears to be consistent with the known safety profile of valganciclovir/ganciclovir.</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Saudi Arabia:</em></p><p dir="ltr"><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:93.8pt;margin-top:7.15pt;width:465.9pt;height:78.5pt;z-index:251660288;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
  o:allowincell="f" filled="f" strokeweight=".16931mm">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText align=left style='margin-left:29.5pt;text-align:left;
     text-indent:-6.45pt;line-height:14.6pt;mso-line-height-rule:exactly;
     mso-list:l1 level1 lfo1;tab-stops:29.55pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol;letter-spacing:.9pt'><span style='mso-list:Ignore'>·</span></span><![endif]><span
     dir=LTR></span>The<span style='letter-spacing:-.2pt'> </span>National<span
     style='letter-spacing:-.2pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.15pt'> </span>Center<span style='letter-spacing:
     -.15pt'> </span><span style='letter-spacing:-.1pt'>(NPC)<o:p></o:p></span></p>
     <p class=MsoBodyText align=left style='margin-left:41.1pt;text-align:left;
     text-indent:-.25in;mso-list:l1 level1 lfo1;tab-stops:41.1pt;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol;letter-spacing:.9pt'><span style='mso-list:Ignore'>·<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>SFDA<span style='letter-spacing:-.15pt'> </span>Call<span
     style='letter-spacing:-.05pt'> </span>Center:<span style='letter-spacing:
     -.05pt'> </span><span style='letter-spacing:-.1pt'>19999<o:p></o:p></span></p>
     <p class=MsoBodyText align=left style='margin-left:41.1pt;text-align:left;
     text-indent:-.25in;mso-list:l1 level1 lfo1;tab-stops:41.1pt;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol;color:#0070C0;letter-spacing:.9pt'><span style='mso-list:Ignore'>·<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='color:#0070C0'>E-mail:<span style='letter-spacing:
     -.25pt'> <a href="mailto:npc.drug@sfda.gov.sa"><span style='color:#0070C0;
     letter-spacing:-.1pt'>npc.d</span></a></span><span style='letter-spacing:
     -.1pt'><a href="mailto:rug@sfda.gov.sa"><span style='color:#0070C0'>rug@sfda.gov.sa</span></a><o:p></o:p></span></span></p>
     <p class=MsoBodyText align=left style='margin-left:41.1pt;text-align:left;
     text-indent:-.25in;mso-list:l1 level1 lfo1;tab-stops:41.1pt;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol;color:#0070C0;letter-spacing:.9pt'><span style='mso-list:Ignore'>·<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='color:#0070C0'>Website:<span style='letter-spacing:
     -.4pt'> </span><u><span style='letter-spacing:-.1pt'>https://ade.sfda.gov.sa/</span></u><span
     style='letter-spacing:-.1pt'><o:p></o:p></span></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" dir="ltr"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="626" height="110" alt="Text Box: •	The National Pharmacovigilance Center (NPC)
•	SFDA Call Center: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: https://ade.sfda.gov.sa/
" src="file:///C:/Users/USER/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p dir="ltr"><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Overdose experience with valganciclovir and intravenous ganciclovir</u></p><p dir="ltr">It is expected that an overdose of valganciclovir could possibly result in increased renal toxicity.</p><p dir="ltr">Reports of overdoses with intravenous ganciclovir, some with fatal outcomes, have been received from clinical trials and during post-marketing experience. In some of these cases no adverse events were reported. The majority of patients experienced one or more of the following adverse events:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; <em>Haematological toxicity: </em>myelosuppression including pancytopenia, bone marrow failure, leukopenia, neutropenia, granulocytopenia.</p><p dir="ltr">-&nbsp;&nbsp; <em>Hepatotoxicity: </em>hepatitis, liver function disorder.</p><p dir="ltr">-&nbsp; <em>Renal toxicity: </em>worsening of haematuria in a patient with pre-existing renal impairment, acute kidney injury, elevated creatinine.</p><p dir="ltr">-&nbsp;&nbsp; <em>Gastrointestinal toxicity: </em>abdominal pain, diarrhoea, vomiting.</p><p dir="ltr">-&nbsp;&nbsp; <em>Neurotoxicity: </em>generalised tremor, seizure.</p><p dir="ltr">Haemodialysis and hydration may be of benefit in reducing blood plasma levels in patients who receive an overdose of valganciclovir.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Antivirals for systemic use, nucleosides and nucleotides excl. reverse transcriptase inhibitors, ATC code: J05A B14.</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Valganciclovir is an L-valyl ester (prodrug) of ganciclovir. After oral administration, valganciclovir is rapidly and extensively metabolised to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2&#39;-deoxyguanosine and inhibits replication of herpes viruses in vitro and in vivo. Sensitive human viruses include human cytomegalovirus</p><p dir="ltr">&nbsp;</p><p dir="ltr">(HCMV), herpes simplex virus-1 and -2 (HSV-1 and HSV-2), human herpes virus -6, -7 and - 8 (HHV-6, HHV-7, HHV8), Epstein-Barr virus (EBV), varicella-zoster virus (VZV) and hepatitis B virus (HBV).</p><p dir="ltr">In CMV-infected cells, ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, pUL97. Further phosphorylation occurs by cellular kinases to produce ganciclovir triphosphate, which is then slowly metabolised intracellularly. Triphosphate metabolism has been shown to occur in HSV- and HCMV- infected cells with half-lives of 18 and between 6 and 24 hours respectively, after the removal of extracellular ganciclovir. As the phosphorylation is largely dependent on the viral kinase, phosphorylation of ganciclovir occurs preferentially in virus-infected cells.</p><p dir="ltr">The virustatic activity of ganciclovir is due to inhibition of viral DNA synthesis by: (a) competitive inhibition of incorporation of deoxyguanosine-triphosphate into DNA by viral DNA polymerase, and (b) incorporation of ganciclovir triphosphate into viral DNA causing termination of, or very limited, further viral DNA elongation.</p><p dir="ltr"><u>Antiviral activity</u></p><p dir="ltr">The in-vitro anti-viral activity, measured as IC50 of ganciclovir against CMV, is in the range of 0.08 &mu;M (0.02 &mu;g/ml) to 14 &mu;M (3.5 &mu;g/ml).</p><p dir="ltr">The clinical antiviral effect of valganciclovir has been demonstrated in the treatment of AIDS patients with newly diagnosed CMV retinitis. CMV shedding was decreased in urine from 46</p><p dir="ltr">% (32/69) of patients at study entry to 7 % (4/55) of patients following four weeks of valganciclovir treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The pharmacokinetic properties of valganciclovir have been evaluated in HIV- and CMV- seropositive patients, patients with AIDS and CMV retinitis and in solid organ transplant patients.</p><p dir="ltr">Dose proportionality with respect to ganciclovir AUC following administration of valganciclovir in the dose range 450 to 2625 mg was demonstrated only under fed conditions. <u>Absorption</u></p><p dir="ltr">Valganciclovir is a prodrug of ganciclovir. It is well absorbed from the gastrointestinal tract and rapidly and extensively metabolised in the intestinal wall and liver to ganciclovir. Systemic exposure to valganciclovir is transient and low. The bioavailability of ganciclovir from oral dosing of valganciclovir is approximately 60 % across all the patient populations studied and</p><p dir="ltr">&nbsp;</p><p dir="ltr">the resultant exposure to ganciclovir is similar to that after its intravenous administration (please see below). For comparison, the bioavailability of ganciclovir after administration of 1000 mg oral ganciclovir (as capsules) is 6 - 8 %.</p><p dir="ltr"><em>Valganciclovir in HIV positive, CMV positive patients:</em></p><p dir="ltr">Systemic exposure of HIV positive, CMV positive patients after twice daily administration of ganciclovir and valganciclovir for one week is:</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter</p></td><td rowspan="2" style="vertical-align:top"><p>Ganciclovir (5 mg/kg, i.v.)</p><p>n = 18</p></td><td colspan="2" style="vertical-align:top"><p>Valganciclovir (900 mg, p.o.) n = 25</p></td></tr><tr><td style="vertical-align:top"><p>Ganciclovir</p></td><td style="vertical-align:top"><p>Valganciclovir</p></td></tr><tr><td style="vertical-align:top"><p>AUC(0 - 12 h) (&mu;g.h/ml)</p></td><td style="vertical-align:top"><p>28.6 &plusmn; 9.0</p></td><td style="vertical-align:top"><p>32.8 &plusmn; 10.1</p></td><td style="vertical-align:top"><p>0.37 &plusmn; 0.22</p></td></tr><tr><td style="vertical-align:top"><p>Cmax (&mu;g/ml)</p></td><td style="vertical-align:top"><p>10.4 &plusmn; 4.9</p></td><td style="vertical-align:top"><p>6.7 &plusmn; 2.1</p></td><td style="vertical-align:top"><p>0.18 &plusmn; 0.06</p></td></tr></tbody></table><p dir="ltr">The efficacy of ganciclovir in increasing the time-to-progression of CMV retinitis has been shown to correlate with systemic exposure (AUC).</p><p dir="ltr"><em>Valganciclovir in solid organ transplant patients:</em></p><p dir="ltr">Steady state systemic exposure of solid organ transplant patients to ganciclovir after daily oral administration of ganciclovir and valganciclovir is:</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter</p></td><td rowspan="2" style="vertical-align:top"><p>Ganciclovir (1000 mg t.i.d.)</p><p>n = 82</p></td><td style="vertical-align:top"><p>Valganciclovir (900 mg, od) n = 161</p></td></tr><tr><td style="vertical-align:top"><p>Ganciclovir</p></td></tr><tr><td style="vertical-align:top"><p>AUC(0 - 24 h) (&mu;g.h/ml)</p></td><td style="vertical-align:top"><p>28.0 &plusmn; 10.9</p></td><td style="vertical-align:top"><p>46.3 &plusmn; 15.2</p></td></tr><tr><td style="vertical-align:top"><p>Cmax (&mu;g/ml)</p></td><td style="vertical-align:top"><p>1.4 &plusmn; 0.5</p></td><td style="vertical-align:top"><p>5.3 &plusmn; 1.5</p></td></tr></tbody></table><p dir="ltr">The systemic exposure of ganciclovir to heart, kidney and liver transplant recipients was similar after oral administration of valganciclovir according to the renal function dosing algorithm.</p><p dir="ltr"><em>Food effect:</em></p><p dir="ltr">When valganciclovir was given with food at the recommended dose of 900 mg, higher values were seen in both mean ganciclovir AUC (approximately 30 %) and mean ganciclovir Cmax values (approximately 14 %) than in the fasting state. Also, the inter-individual variation in exposure of ganciclovir decreases when taking Valganciclovir with food. Valganciclovir has only been administered with food in clinical studies. Therefore, it is recommended that Valganciclovir be administered with food.</p><p dir="ltr"><u>Distribution:</u></p><p dir="ltr">Because of rapid conversion of valganciclovir to ganciclovir, protein binding of valganciclovir was not determined. The steady state volume of distribution (Vd) of ganciclovir after</p><p dir="ltr">&nbsp;</p><p dir="ltr">intravenous administration was 0.680 &plusmn; 0.161 l/kg (n=114). For IV ganciclovir, the volume of distribution is correlated with body weight with values for the steady state volume of distribution ranging from 0.54-0.87 L/kg. Ganciclovir penetrates the cerebrospinal fluid. Binding to plasma proteins was 1%-2% over ganciclovir concentrations of 0.5 and 51 &micro;g/mL.</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr">Valganciclovir is rapidly and extensively metabolised to ganciclovir; no other metabolites have been detected. Ganciclovir itself is not metabolised to a significant extent.</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">Following dosing with oral valganciclovir, the drug is rapidly hydrolysed to ganciclovir. Ganciclovir is eliminated from the systemic circulation by glomerular filtration and active tubular secretion. In patients with normal renal function greater than 90% of IV administered ganciclovir was recovered un-metabolized in the urine within 24 hours. In patients with normal renal function the post-peak plasma concentrations of ganciclovir after administration of valganciclovir decline with a half-life ranging from 0.4 h to 2.0 h.</p><p dir="ltr"><u>Pharmacokinetics in special clinical situations</u></p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">In a phase II pharmacokinetic and safety study in paediatric solid organ transplant recipients (aged 4 months to 16 years, n = 63) valganciclovir was given once daily for up to 100 days. Pharmacokinetic parameters were similar across organ type and age range and comparable with adults. Population pharmacokinetic modeling suggested that bioavailability was approximately 60%. Clearance was positively influenced by both body surface area and renal function.</p><p dir="ltr">In a phase I pharmacokinetic and safety study in paediatric heart transplant recipients (aged 3 weeks to 125 days, n = 14), valganciclovir was given once daily for two study days. Population pharmacokinetics estimated that mean bioavailability was 64%.</p><p dir="ltr">A comparison of the results from these two studies and the pharmacokinetic results from the adult population shows that ranges of AUC 0-24h were very similar across all age groups, including adults. Mean values for AUC0-24h and Cmax were also similar across the paediatric age groups &lt; 12 years old, although there was a trend of decreasing mean values for AUC0- 24h and Cmax across the entire pediatric age range, which appeared to correlate with increasing age. This trend was more apparent for mean values of clearance and half-life (t1/2); however this is to be expected as clearance is influenced by changes in weight, height and renal function associated with patient growth, as indicated by population pharmacokinetic modelling.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The following table summarizes the model-estimated AUC0-24h ranges for ganciclovir from these two studies, as well as mean and standard deviation values for AUC0-24h, Cmax, CL and t &frac12; for the relevant paediatric age groups compared to adult data:</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>PK Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Adults*</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Paediatrics</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&ge; 18 years</strong></p></td><td style="vertical-align:top"><p><strong>&lt; 4 months</strong></p></td><td style="vertical-align:top"><p><strong>4 months - &le; 2</strong></p></td><td style="vertical-align:top"><p><strong>&gt; 2 - &lt; 12</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 12 years &ndash;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>(n=160)</strong></p></td><td style="vertical-align:top"><p><strong>(n = 14)</strong></p></td><td style="vertical-align:top"><p><strong>years</strong></p></td><td style="vertical-align:top"><p><strong>years</strong></p></td><td style="vertical-align:top"><p><strong>16 years</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>(n=17)</strong></p></td><td style="vertical-align:top"><p><strong>(n=21)</strong></p></td><td style="vertical-align:top"><p><strong>(n=25)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC<sub>0-24h</sub> (&mu;g<sup>.</sup>h/ml)</strong></p></td><td style="vertical-align:top"><p>46.3 &plusmn; 15.2</p></td><td style="vertical-align:top"><p>68.1 &plusmn; 19.8</p></td><td style="vertical-align:top"><p>64.3 &plusmn; 29.2</p></td><td style="vertical-align:top"><p>59.2 &plusmn; 15.1</p></td><td style="vertical-align:top"><p>50.3 &plusmn; 15.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Range of AUC<sub>0-24h</sub></strong></p></td><td style="vertical-align:top"><p>15.4 &ndash; 116.1</p></td><td style="vertical-align:top"><p>34 - 124</p></td><td style="vertical-align:top"><p>34 - 152</p></td><td style="vertical-align:top"><p>36 - 108</p></td><td style="vertical-align:top"><p>22 - 93</p></td></tr><tr><td style="vertical-align:top"><p><strong>C<sub>max</sub> (&mu;g/ml)</strong></p></td><td style="vertical-align:top"><p>5.3 &plusmn; 1.5</p></td><td style="vertical-align:top"><p>10.5 &plusmn; 3.36</p></td><td style="vertical-align:top"><p>10.3 &plusmn; 3.3</p></td><td style="vertical-align:top"><p>9.4 &plusmn; 2.7</p></td><td style="vertical-align:top"><p>8.0 &plusmn; 2.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clearance (l/h)</strong></p></td><td style="vertical-align:top"><p>12.7 &plusmn; 4.5</p></td><td style="vertical-align:top"><p>1.25 &plusmn; 0.473</p></td><td style="vertical-align:top"><p>2.5 &plusmn; 2.4</p></td><td style="vertical-align:top"><p>4.5 &plusmn; 2.9</p></td><td style="vertical-align:top"><p>6.4 &plusmn; 2.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>t<sub>1/2</sub> (h)</strong></p></td><td style="vertical-align:top"><p>6.5 &plusmn; 1.4</p></td><td style="vertical-align:top"><p>1.97 &plusmn; 0.185</p></td><td style="vertical-align:top"><p>3.1 &plusmn;1.4</p></td><td style="vertical-align:top"><p>4.1 &plusmn; 1.3</p></td><td style="vertical-align:top"><p>5.5 &plusmn; 1.1</p></td></tr></tbody></table><p dir="ltr">* Extracted from study report PV 16000</p><p dir="ltr">The once daily dose of valganciclovir in both of the studies described above was based on body surface area (BSA) and creatinine clearance (CrCl) derived from a modified Schwartz formula, and was calculated using the dosing algorithm presented in section 4.2.</p><p dir="ltr">Ganciclovir pharmacokinetics following valganciclovir administration were also evaluated in two studies in neonates and infants with symptomatic congenital CMV disease. In the first study 24 neonates aged 8 to 34 days received 6 mg/kg intravenous ganciclovir twice daily. Patients were then treated with oral valganciclovir, where the dose of valganciclovir powder for oral solution ranged from 14 mg/kg to 20 mg/kg twice daily; total treatment duration was 6 weeks. A dose of 16 mg/kg twice daily of valganciclovir powder for oral solution provided comparable ganciclovir exposure as 6 mg/kg intravenous ganciclovir twice daily in neonates, and also achieved ganciclovir exposure similar to the effective adult 5 mg/kg intravenous dose. In the second study, 109 neonates aged 2 to 30 days received 16 mg/kg valganciclovir powder for oral solution twice daily for 6 weeks and subsequently 96 out of 109 enrolled patients were randomized to continue receiving valganciclovir or placebo for 6 months. However, the mean AUC0-12h was lower compared to the mean AUC0-12h values from the first study. The following table shows the mean values of AUC, Cmax, and t&frac12; including standard deviations compared with adult data:</p><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>PK Parameter</strong></p></td><td style="vertical-align:top"><p>Adults</p></td><td colspan="3" style="vertical-align:top"><p>Paediatrics (neonates and infants)</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>5 mg/kg GAN</strong></p></td><td style="vertical-align:top"><p><strong>6 mg/kg GAN</strong></p></td><td style="vertical-align:top"><p><strong>16 mg/kg</strong></p></td><td style="vertical-align:top"><p><strong>16 mg/kg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Single dose</strong></p></td><td style="vertical-align:top"><p><strong>Twice daily</strong></p></td><td style="vertical-align:top"><p><strong>VAL</strong></p></td><td style="vertical-align:top"><p><strong>VAL</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>(n=8)</strong></p></td><td style="vertical-align:top"><p><strong>(n=19)</strong></p></td><td style="vertical-align:top"><p><strong>Twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Twice daily</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>(n=19)</strong></p></td><td style="vertical-align:top"><p><strong>(n = 100)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC<sub>0-&infin;</sub> (&mu;g<sup>.</sup>h/mL)</strong></p></td><td style="vertical-align:top"><p>25.4 &plusmn; 4.32</p></td><td style="vertical-align:top"><p><strong>-</strong></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC<sub>0-12h</sub> (&mu;g<sup>.</sup>h/mL)</strong></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>38.2 &plusmn; 42.7</p></td><td style="vertical-align:top"><p>30.1 &plusmn; 15.1</p></td><td style="vertical-align:top"><p>20.85 &plusmn; 5.40</p></td></tr><tr><td style="vertical-align:top"><p><strong>C<sub>max</sub> (&mu;g/ml)</strong></p></td><td style="vertical-align:top"><p>9.03 &plusmn; 1.26</p></td><td style="vertical-align:top"><p>12.9 &plusmn; 21.5</p></td><td style="vertical-align:top"><p>5.44 &plusmn; 4. 04</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>t<sub>1/2</sub> (h)</strong></p></td><td style="vertical-align:top"><p>3.32 &plusmn; 0.47</p></td><td style="vertical-align:top"><p>2.52 &plusmn; 0. 55</p></td><td style="vertical-align:top"><p>2.98 &plusmn; 1. 26</p></td><td style="vertical-align:top"><p>2.98 &plusmn; 1.12</p></td></tr></tbody></table><p dir="ltr">GAN = Ganciclovir, i.v. VAL = Valganciclovir, oral</p><p dir="ltr">These data are too limited to allow conclusions regarding efficacy or posology recommendations for paediatric patients with congenital CMV infection.</p><p dir="ltr"><em>Elderly</em></p><p dir="ltr">No investigations on valganciclovir or ganciclovir pharmacokinetics in adults older than 65 years of age have been undertaken.</p><p dir="ltr"><em>Patients with renal impairment</em></p><p dir="ltr">The pharmacokinetics of ganciclovir from a single oral dose of 900 mg valganciclovir was evaluated in 24 otherwise healthy individuals with renal impairment.</p><p dir="ltr">Pharmacokinetic parameters of ganciclovir from a single oral dose of 900 mg Valganciclovir tablets in patients with various degrees of renal impairment:</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>Estimated Creatinine Clearance (mL/min)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Apparent Clearance (mL/min) Mean </strong>&plusmn; <strong>SD</strong></p></td><td style="vertical-align:top"><p><strong>AUClast (&mu;g∙h/mL) Mean </strong>&plusmn; <strong>SD</strong></p></td><td style="vertical-align:top"><p><strong>Half-life (hours) Mean </strong>&plusmn; <strong>SD</strong></p></td></tr><tr><td style="vertical-align:top"><p>51-70</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>249 &plusmn; 99</p></td><td style="vertical-align:top"><p>49.5 &plusmn; 22.4</p></td><td style="vertical-align:top"><p>4.85 &plusmn; 1.4</p></td></tr><tr><td style="vertical-align:top"><p>21-50</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>136 &plusmn; 64</p></td><td style="vertical-align:top"><p>91.9 &plusmn; 43.9</p></td><td style="vertical-align:top"><p>10.2 &plusmn; 4.4</p></td></tr><tr><td style="vertical-align:top"><p>11-20</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>45 &plusmn; 11</p></td><td style="vertical-align:top"><p>223 &plusmn; 46</p></td><td style="vertical-align:top"><p>21.8 &plusmn; 5.2</p></td></tr><tr><td style="vertical-align:top"><p>&le;10</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>12.8 &plusmn; 8</p></td><td style="vertical-align:top"><p>366 &plusmn; 66</p></td><td style="vertical-align:top"><p>67.5 &plusmn; 34</p></td></tr></tbody></table><p dir="ltr">Decreasing renal function resulted in decreased clearance of ganciclovir from Valganciclovir with a corresponding increase in terminal half-life. Therefore, dosage adjustment is required for renally impaired patients.</p><p dir="ltr"><em>Patients undergoing haemodialysis</em></p><p dir="ltr">For patients receiving haemodialysis dose recommendations for valganciclovir 450 mg film- coated tablets cannot be given. This is because an individual dose of valganciclovir required</p><p dir="ltr">&nbsp;</p><p dir="ltr">for these patients is less than the 450 mg tablet strength. Thus, valganciclovir film-coated tablets should not be used in these patients.</p><p dir="ltr"><em>Stable liver transplant patients</em></p><p dir="ltr">The pharmacokinetics of ganciclovir from valganciclovir in stable liver transplant patients were investigated in one open label 4-part crossover study (N=28). The bioavailability of ganciclovir from valganciclovir, following a single dose of 900 mg valganciclovir under fed conditions, was approximately 60%. Ganciclovir AUC0-24h was comparable to that achieved by 5 mg/kg intravenous ganciclovir in liver transplant patients.</p><p dir="ltr"><em>Patients with hepatic impairment</em></p><p dir="ltr">The safety and efficacy of valganciclovir film-coated tablets have not been studied in patients with hepatic impairment. Hepatic impairment should not affect the pharmacokinetics of ganciclovir since it is excreted renally and, therefore, no specific dose recommendation is made.</p><p dir="ltr"><em>Patients with cystic fibrosis</em></p><p dir="ltr">In a phase I pharmacokinetic study in lung transplant recipients with or without cystic fibrosis (CF), 31 patients (16 CF/15 non-CF) received post-transplant prophylaxis with 900 mg/day valganciclovir. The study indicated that cystic fibrosis had no statistically significant influence on the overall average systemic exposure to ganciclovir in lung transplant recipients. Ganciclovir exposure in lung transplant recipients was comparable to that shown to be efficacious in the prevention of CMV disease in other solid organ transplant recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Valganciclovir is a pro-drug of ganciclovir and therefore effects observed with ganciclovir apply equally to valganciclovir. Toxicity of valganciclovir in pre-clinical safety studies was the same as that seen with ganciclovir and was induced at ganciclovir exposure levels comparable to, or lower than, those in humans given the induction dose.</p><p dir="ltr">These findings were gonadotoxicity (testicular cell loss) and nephrotoxicity (uraemia, cell degeneration), which were irreversible; myelotoxicity (anaemia, neutropenia, lymphocytopenia) and gastrointestinal toxicity (mucosal cell necrosis), which were reversible. Ganciclovir was mutagenic in mouse lymphoma cells and clastogenic in mammalian cells. Such results are consistent with the positive mouse carcinogenicity study with ganciclovir. Ganciclovir is a potential carcinogen.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Further studies have shown ganciclovir to be teratogenic, embryotoxic, to inhibit spermatogenesis (i.e. impair male fertility) and to suppress female fertility.</p><p dir="ltr">Animal data indicate that ganciclovir is excreted in the milk of lactating rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">1.1&nbsp; <u>Tablet core:</u></p><p dir="ltr">Cellulose Microcrystalline (PH 101) Crospovidone (Type B)</p><p dir="ltr">Povidone (K- 30)</p><p dir="ltr">Cellulose Microcrystalline (PH 102) Magnesium stearate</p><p dir="ltr"><strong><u>Tablet coating:</u></strong></p><p dir="ltr">Opadry Pink YS-1-14519A contains:</p><p dir="ltr">Hypromellose Titanium Dioxide Macrogol 400</p><p dir="ltr">Polysorbate 80 Iron Oxide Red</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store below 30<sup>0</sup>C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Blister pack</p><p dir="ltr">Valgaset 450 mg are supplied in 60&rsquo;s pack (10&rsquo;s Blister x 6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aurobindo Pharma Saudi Arabia Limited, Jeddah, Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2021.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>